NEW YORK (GenomeWeb) – Proteome Sciences said today that it has signed a $2 million contract with Genting TauRx Diagnostic Centre, an affiliate of TauRx Therapeutics, to provide protein biomarker work in support of the company's Phase III trial of its Alzheimer's drug LMTX.

Proteome Sciences will analyze blood samples from patients enrolled in the trial and from age-matched controls with the aim of building protein panels for the detection of Alzheimer's and for monitoring treatment efficacy.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

The World Health Organization has announced the members of its gene-editing committee, according to NPR.

DARPA is working on developing algorithms that gauge the credibility of research findings, Wired reports.

The American Society of Breast Surgeons recommends all women diagnosed with breast cancer be offered genetic testing, the Washington Post says.

In Science this week: comparison of modern, historical rabbit exomes uncovers parallel evolution after myxoma virus exposure; and more.

Feb
21
Sponsored by
L7 Informatics

This webinar will provide a first-hand look at how Gradalis, a clinical-stage immunotherapy developer, is using an information management solution from L7 to streamline its research, clinical, and manufacturing operations.

Mar
27
Sponsored by
Swift Biosciences

Sequencing workflows require library quantification and normalization to ensure data quality and reduce cost.